"Ceftazidime" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients.
| Descriptor ID |
D002442
|
| MeSH Number(s) |
D02.065.589.099.249.210.150 D02.886.665.074.210.150 D03.633.100.300.249.210.150
|
| Concept/Terms |
Ceftazidime- Ceftazidime
- Ceftazidime Pentahydrate
- Pentahydrate, Ceftazidime
|
Below are MeSH descriptors whose meaning is more general than "Ceftazidime".
Below are MeSH descriptors whose meaning is more specific than "Ceftazidime".
This graph shows the total number of publications written about "Ceftazidime" by people in this website by year, and whether "Ceftazidime" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 2 | 3 |
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 3 | 5 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 1 | 3 |
| 2018 | 0 | 2 | 2 |
| 2020 | 2 | 1 | 3 |
| 2022 | 3 | 0 | 3 |
| 2023 | 4 | 0 | 4 |
| 2024 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ceftazidime" by people in Profiles.
-
In vitro evaluation of using ceftazidime/avibactam against carbapenem-resistant Acinetobacter baumannii. J Glob Antimicrob Resist. 2024 Sep; 38:252-255.
-
The mechanism of ceftazidime and cefiderocol hydrolysis by D179Y variants of KPC carbapenemases is similar and involves the formation of a long-lived covalent intermediate. Antimicrob Agents Chemother. 2024 Mar 06; 68(3):e0110823.
-
Structural insights into the molecular mechanism of high-level ceftazidime-avibactam resistance conferred by CMY-185. mBio. 2024 Feb 14; 15(2):e0287423.
-
Klebsiella pneumoniae carbapenemase variant 44 acquires ceftazidime-avibactam resistance by altering the conformation of active-site loops. J Biol Chem. 2024 Jan; 300(1):105493.
-
High-level ceftazidime/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated ?-lactamase CMY-185 variant. J Antimicrob Chemother. 2023 10 03; 78(10):2442-2450.
-
A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE)?bloodstream infections. Int J Antimicrob Agents. 2023 Apr; 61(4):106760.
-
Mapping the determinants of catalysis and substrate specificity of the antibiotic resistance enzyme CTX-M ?-lactamase. Commun Biol. 2023 01 12; 6(1):35.
-
Deciphering longitudinal optical-density measurements to guide clinical dosing regimen design: A model-based approach. Comput Methods Programs Biomed. 2022 Dec; 227:107212.
-
Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2022 10 28; 77(11):3130-3137.
-
Slow Protein Dynamics Elicits New Enzymatic Functions by Means of Epistatic Interactions. Mol Biol Evol. 2022 10 07; 39(10).